President Barack Obama has written a game plan on health care for the next president, including a crackdown on prescription drug prices that may cut pharmaceutical manufacturers’ profits if adopted.
A hot-selling drug for diabetes sold by Eli Lilly and Co. and a co-partner just got another potential boost, as a government panel narrowly recommended that the companies should be allowed to claim that the drug cuts the risk of cardiovascular death.
The West Lafayette-based company has named CFO and COO Mike Sherman as new CEO and president, but did not give a reason for the abrupt change in leadership.
Biochemist has founded or co-founded five startups since retiring from Eli Lilly and Co. as head of biotechnology research 13 years ago, at age 50.
Upon his arrival in Indianapolis, Clowes began aggressively pursuing research that might lead to mass-produced pharmaceuticals.
A Medicare proposal to test new ways of paying for chemotherapy and other drugs given in a doctor's office has sparked a furious battle, and cancer doctors are demanding that the Obama administration scrap the experiment.
The three drugmakers that dominate the world diabetes market—Eli Lilly and Co., Novo Nordisk A/S and Sanofi—are introducing improved forms of insulin, with a price tag to match.
The biggest U.S.-based drugmaker, Pfizer Inc., will stay put thanks to aggressive new Treasury Department rules that succeeded in blocking Pfizer from acquiring rival Allergan and moving to Ireland—on paper—to reduce its tax bill.
A small manufacturer angling to pick up more business in Indiana makes cold and allergy medicine resistant to being abused by methamphetamine makers.
Within six months, Eli Lilly and Co. could know whether the Food and Drug Administration has approved its latest drug, baricitinib, a once-a-day tablet for treating rheumatoid arthritis.
For Eli Lilly and Co., the approval rewards a decade-long effort to re-enter the biotech and autoimmune spaces that it helped pioneer in the 1980s but then abandoned in the 1990s.
Express Scripts Holding Co.’s incoming CEO is trying to keep its biggest customer after Anthem Inc. sued to recoup billions of dollars in what it called excess payments for drugs and threatened to end their relationship.
Pharmacists in Indiana will be able to limit how much cold medicine customers can buy under a measure Indiana Gov. Mike Pence signed into law Monday.
The insurer’s CEO said in January that Anthem should be reaping an addition $3 billion per year in savings on drugs from Express Scripts, which manages its pharmacy benefits.
Two measures aimed at to reducing methamphetamine production in Indiana are on their way to the governor's desk after receiving approval from the full House.
The erectile-dysfunction drug, made famous by a slew of quirky commercials, is facing performance issues of its own.
Teva’s acquisition will make it the world’s largest maker of generic medicines, giving it greater negotiating power with governments and private-health insurers.
Bills would let pharmacists require prescriptions for suspicious customers trying to buy cold medicines with pseudoephedrine. But some drug store chains fear putting their pharmacists in danger.
The supermarket chain will make naloxone available in its pharmacies across Ohio and northern Kentucky, a region hard-hit by deadly heroin.
The new version of the Indiana bill would classify pseudoephedrine in a way that most consumers would be able to buy it, but pharmacists could require a prescription from suspicious customers.
